• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Dopa Responsiveness in Parkinson's Disease.帕金森病中的多巴反应性。
Mov Disord Clin Pract. 2024 Sep;11(9):1113-1124. doi: 10.1002/mdc3.14139. Epub 2024 Jun 19.
2
Use of β-adrenoreceptor drugs and Parkinson's disease incidence in women from the French E3N cohort study.来自法国E3N队列研究的女性中β-肾上腺素能受体药物的使用与帕金森病发病率
J Parkinsons Dis. 2025 Apr 29:1877718X251330993. doi: 10.1177/1877718X251330993.
3
One-year practice effects predict long-term cognitive outcomes in Parkinson's disease.一年的练习效果可预测帕金森病的长期认知结果。
J Parkinsons Dis. 2025 Apr 29:1877718X251339585. doi: 10.1177/1877718X251339585.
4
Mild cognitive impairment is not predictive of dementia up to 15 years after subthalamic deep brain stimulation in Parkinson's disease.在帕金森病中,丘脑底核深部脑刺激术后长达15年的时间里,轻度认知障碍并不能预测痴呆。
J Parkinsons Dis. 2025 Jun;15(4):879-891. doi: 10.1177/1877718X251334049. Epub 2025 May 20.
5
St Andrews Referral Delay in Skin Cancer (StARDISC): a study of keratinocyte skin cancer time to treatment, growth, invasiveness, British Association of Dermatologists risk factors and excision adequacy.圣安德鲁斯皮肤癌转诊延迟研究(StARDISC):一项关于角质形成细胞皮肤癌治疗时间、生长、侵袭性、英国皮肤科医师协会危险因素及切除充分性的研究。
Br J Dermatol. 2025 Jun 20;193(1):157-166. doi: 10.1093/bjd/ljaf097.
6
Electronic cigarettes for smoking cessation.用于戒烟的电子烟。
Cochrane Database Syst Rev. 2025 Jan 29;1(1):CD010216. doi: 10.1002/14651858.CD010216.pub9.
7
Incidence of antiepileptic drug use in Parkinson's disease.帕金森病中抗癫痫药物的使用发生率。
J Parkinsons Dis. 2025 Jun;15(4):780-788. doi: 10.1177/1877718X251343079. Epub 2025 May 23.
8
Dementia risk prediction in early Parkinson's disease: Validation and genetic integration of the Montreal Parkinson risk of dementia scale (MoPaRDS).早期帕金森病的痴呆风险预测:蒙特利尔帕金森痴呆风险量表(MoPaRDS)的验证与基因整合
J Parkinsons Dis. 2025 Apr 29:1877718X251329857. doi: 10.1177/1877718X251329857.
9
Intestinal biomarkers, microbiota composition, and genetic predisposition to inflammatory bowel disease as predictors of Parkinson's disease manifestation.肠道生物标志物、微生物群组成以及炎症性肠病的遗传易感性作为帕金森病表现的预测指标。
J Parkinsons Dis. 2025 May 7:1877718X251328567. doi: 10.1177/1877718X251328567.
10
Aural toilet (ear cleaning) for chronic suppurative otitis media.慢性化脓性中耳炎的耳道清理(耳部清洁)
Cochrane Database Syst Rev. 2025 Jun 9;6(6):CD013057. doi: 10.1002/14651858.CD013057.pub3.

引用本文的文献

1
Pharmacotherapy in Early Parkinson's Disease: A Pragmatic Approach.早期帕金森病的药物治疗:一种实用方法
Ann Indian Acad Neurol. 2025 Jul 1;28(4):512-518. doi: 10.4103/aian.aian_676_25. Epub 2025 Aug 14.

本文引用的文献

1
Response to levodopa in Parkinson's disease over time. A 4-year follow-up study.帕金森病患者对左旋多巴的反应随时间的变化。一项为期 4 年的随访研究。
Parkinsonism Relat Disord. 2023 Nov;116:105852. doi: 10.1016/j.parkreldis.2023.105852. Epub 2023 Oct 3.
2
Association of caregiver strain with the trajectory of quality of life in Parkinson's disease.照料者负担与帕金森病患者生活质量轨迹的关联。
Parkinsonism Relat Disord. 2023 Mar;108:105292. doi: 10.1016/j.parkreldis.2023.105292. Epub 2023 Jan 23.
3
Heterogeneous pain trajectories in persons with Parkinson's disease.帕金森病患者的异质性疼痛轨迹。
Parkinsonism Relat Disord. 2022 Sep;102:42-50. doi: 10.1016/j.parkreldis.2022.07.006. Epub 2022 Jul 18.
4
Is Levodopa Response a Valid Indicator of Parkinson's Disease?左旋多巴反应是否能有效指示帕金森病?
Mov Disord. 2021 Apr;36(4):948-954. doi: 10.1002/mds.28406. Epub 2020 Nov 30.
5
Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide.左旋多巴等效剂量转换因子:一项包括奥匹卡朋和沙芬酰胺的更新提案。
Mov Disord Clin Pract. 2020 Mar 16;7(3):343-345. doi: 10.1002/mdc3.12921. eCollection 2020 Apr.
6
L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression.早期帕金森病患者对 L-多巴的反应与运动进展速度有关。
Parkinsonism Relat Disord. 2019 Aug;65:55-61. doi: 10.1016/j.parkreldis.2019.05.022. Epub 2019 May 14.
7
Comparing two randomized deep brain stimulation trials for Parkinson's disease.比较两项针对帕金森病的随机深部脑刺激试验。
J Neurosurg. 2019 Apr 5;132(5):1376-1384. doi: 10.3171/2018.12.JNS182042. Print 2020 May 1.
8
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.帕金森病进展标志物计划(PPMI)——建立帕金森病生物标志物队列。
Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477. doi: 10.1002/acn3.644. eCollection 2018 Dec.
9
Two-Year Trajectory of Fall Risk in People With Parkinson Disease: A Latent Class Analysis.帕金森病患者跌倒风险的两年轨迹:一项潜在类别分析
Arch Phys Med Rehabil. 2016 Mar;97(3):372-379.e1. doi: 10.1016/j.apmr.2015.10.105. Epub 2015 Dec 1.
10
MDS clinical diagnostic criteria for Parkinson's disease.帕金森病的MDS临床诊断标准。
Mov Disord. 2015 Oct;30(12):1591-601. doi: 10.1002/mds.26424.

帕金森病中的多巴反应性。

Dopa Responsiveness in Parkinson's Disease.

机构信息

School of Neuroscience and Psychology, University of Glasgow, Glasgow, United Kingdom.

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

出版信息

Mov Disord Clin Pract. 2024 Sep;11(9):1113-1124. doi: 10.1002/mdc3.14139. Epub 2024 Jun 19.

DOI:10.1002/mdc3.14139
PMID:38898616
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11452786/
Abstract

BACKGROUND

Dopaminergic responsiveness is a defining feature of Parkinson's disease (PD). However, there is limited information on how this evolves over time.

OBJECTIVES

To examine serial dopaminergic responses, if there are distinct patterns, and which factors predict these.

METHODS

We analyzed data from the Parkinson's Progression Markers Initiative on repeated dopaminergic challenge tests (≥24.5% defined as a definite response). Growth-mixture modeling evaluated for different response patterns and multinomial logistic regression tested for predictors of these clusters.

RESULTS

1525 dopaminergic challenge tests were performed in 336 patients. At enrolment, mean age was 61.2 years (SD 9.6), 66.4% were male and disease duration was 0.5 years (SD 0.5). 1 to 2 years after diagnosis, 48.0% of tests showed a definite response, but this proportion increased with longer disease duration (51.1-74.3%). We identified 3 response groups: "Striking" (n = 29, 8.7%); "Excellent" (n = 110; 32.7%) and "Modest" (n = 197, 58.6%). Significant differences were as follows: striking responders commenced treatment earlier (P = 0.02), were less likely to be on dopamine agonist monotherapy (P = 0.01), and had better cognition (P < 0.01) and activities of daily living (P = 0.01). Excellent responders had higher challenge doses (P = 0.03) and were more likely to be on combination therapy (P < 0.01).

CONCLUSION

Three distinct patterns of the dopaminergic response were observed. As the proportion of PD cases with definite dopa responsiveness increased over time, the initial treatment response may be an unreliable diagnostic aid.

摘要

背景

多巴胺反应性是帕金森病(PD)的一个决定性特征。然而,关于其随时间如何演变的信息有限。

目的

检查多巴胺反应的连续变化,如果存在不同的模式,以及哪些因素可以预测这些模式。

方法

我们分析了帕金森病进展标志物倡议中重复多巴胺刺激测试的数据(≥24.5%定义为明确反应)。增长混合模型评估了不同的反应模式,多项逻辑回归检验了这些聚类的预测因素。

结果

在 336 名患者中进行了 1525 次多巴胺刺激测试。入组时,平均年龄为 61.2 岁(标准差 9.6),66.4%为男性,疾病持续时间为 0.5 年(标准差 0.5)。在诊断后 1 至 2 年内,48.0%的测试显示出明确的反应,但随着疾病持续时间的延长,这一比例增加(51.1-74.3%)。我们确定了 3 种反应组:“显著”(n=29,8.7%);“优异”(n=110;32.7%)和“适度”(n=197,58.6%)。显著差异如下:显著反应者开始治疗的时间更早(P=0.02),不太可能单独使用多巴胺激动剂治疗(P=0.01),且认知功能(P<0.01)和日常生活活动(P=0.01)更好。优异反应者的刺激剂量更高(P=0.03),更有可能接受联合治疗(P<0.01)。

结论

观察到三种不同的多巴胺反应模式。随着时间的推移,具有明确多巴胺反应性的 PD 病例比例增加,初始治疗反应可能不再是可靠的诊断辅助手段。